Preliminary study of CT in combination with MRI perfusion imaging to assess hemodynamic changes during angiogenesis in a rabbit model of lung cancer

初步研究CT联合MRI灌注成像技术在兔肺癌模型中评估血管生成过程中血流动力学变化的应用

阅读:1

Abstract

BACKGROUND: This study used CT (computed tomography) and magnetic resonance imaging (MRI) to identify correlations between perfusion parameters for squamous cell lung carcinoma and tumor angiogenesis in a rabbit model of VX2 lung cancer. METHODS: VX2 tumors were implanted in the lungs of 35 New Zealand White rabbits. CT and MRI perfusion scanning were performed on days 14, 17, 21, 25, and 28 after tumor implantation. CT perfusion parameters were perfusion, peak enhanced increment, transit time peak, and blood volume, and MRI perfusion parameters were wash in rate, wash out rate, maximum enhancement rate, and transit time peak. CT and MRI perfusion parameters were obtained at the tumor rim, in the tumor tissue, and in the muscle tissue surrounding the tumor. RESULTS: On CT perfusion imaging, t values for perfusion, peak enhanced increment, and blood volume (tumor rim versus muscle) were 16.31, 11.79, and 5.21, respectively (P < 0.01); t values for perfusion, peak enhanced increment, and blood volume (tumor versus muscle) were 9.87, 4.09, and 5.35, respectively (P < 0.01); and t values for transit time peak were 1.52 (tumor rim versus muscle) and 1.29 (tumor versus muscle), respectively (P > 0.05). On MRI perfusion imaging, t values for wash in rate, wash out rate, and maximum enhancement rate (tumor rim versus muscle) were 18.14, 8.79, and 6.02, respectively (P < 0.01); t values for muscle wash in rate, wash out rate, and maximum enhancement rate (tumor versus muscle) were 9.45, 8.23, and 4.21, respectively (P < 0.01); and t values for transit time peak were 1.21 (tumor rim versus muscle) and 1.05 (tumor versus muscle), respectively (P > 0.05). CONCLUSION: A combination of CT and MRI perfusion imaging demonstrated hemodynamic changes in a rabbit model of VX2 lung cancer, and provides a theoretical foundation for treatment of human squamous cell lung carcinoma.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。